XML 34 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Goodwill and Intangible Assets
12 Months Ended
Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets

Note 8—Goodwill and Intangible Assets

The tables below summarize goodwill and intangible assets activities as of December 31, 2020 and 2019 (in thousands):

 

 

 

Goodwill

 

 

Intangible

Assets

 

Balance, December 31, 2018

 

$

 

 

$

 

Rhythm Xience Acquisition

 

 

12,026

 

 

 

4,360

 

Amortization expense

 

 

 

 

 

(250

)

Balance, December 31, 2019

 

 

12,026

 

 

 

4,110

 

Biotronik License Agreement

 

 

 

 

 

2,000

 

Amortization expense

 

 

 

 

 

(457

)

Balance, December 31, 2020

 

$

12,026

 

 

$

5,653

 

 

 

 

Estimated

Useful

 

Weighted

Average

Remaining

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Life

(in years)

 

Life

(in years)

 

 

Intangible

Assets

 

 

Accumulated

Amortization

 

 

 

December 31,

2020

 

Developed technology

 

10

 

 

8.6

 

 

$

4,200

 

 

$

(600

)

 

 

$

3,600

 

Customer-related intangible

 

5

 

3.5

 

 

 

100

 

 

 

(30

)

 

 

 

70

 

Licensed intangibles

 

10

 

 

9.9

 

 

 

2,000

 

 

 

(17

)

 

 

 

1,983

 

Total

 

 

 

 

 

 

 

$

6,300

 

 

$

(647

)

 

 

$

5,653

 

 

 

 

 

 

 

Estimated

Useful

 

Weighted

Average

Remaining

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Life

(in years)

 

Life

(in years)

 

Intangible

Assets

 

 

Accumulated

Amortization

 

 

December 31,

2019

 

Developed technology

 

10

 

9.5

 

$

3,600

 

 

$

(180

)

 

$

3,420

 

In-process technology

 

indefinite

 

 

 

 

600

 

 

 

 

 

 

600

 

Trademarks and trade names

 

0.5

 

 

 

60

 

 

 

(60

)

 

 

 

Customer-related intangible

 

5

 

4.5

 

 

100

 

 

 

(10

)

 

 

90

 

Total

 

 

 

 

 

$

4,360

 

 

$

(250

)

 

$

4,110

 

 

Acquired in-process technology was classified as an indefinite-lived intangible asset until the receipt of FDA approval for the technology in January 2020. Once FDA approval was received, the in-process technology was reclassified as developed technology and amortization began. The Company recorded amortization expense related to the above intangible assets of $0.5 million and $0.3 million for the years ended December 31, 2020 and 2019, respectively.

The following table shows the remaining amortization expense associated with amortizable intangible assets as of December 31, 2020 (in thousands):

 

 

 

Developed

Technology

 

 

Customer-

Related

Intangible

 

 

Licensed

Intangibles

 

 

Total

Amortization

 

Year ending December 31, 2021

 

$

420

 

 

$

20

 

 

$

200

 

 

$

640

 

Year ending December 31, 2022

 

 

420

 

 

 

20

 

 

 

200

 

 

 

640

 

Year ending December 31, 2023

 

 

420

 

 

 

20

 

 

 

200

 

 

 

640

 

Year ending December 31, 2024

 

 

420

 

 

 

10

 

 

 

200

 

 

 

630

 

Year ending December 31, 2025

 

 

420

 

 

 

 

 

 

200

 

 

 

620

 

Thereafter

 

 

1,500

 

 

 

 

 

 

983

 

 

 

2,483

 

Total

 

$

3,600

 

 

$

70

 

 

$

1,983

 

 

$

5,653